Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H16ClNO3 |
| Molecular Weight | 305.756 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCC2=CN=CC=C2
InChI
InChIKey=RARQHAFNGNPQCZ-UHFFFAOYSA-N
InChI=1S/C16H16ClNO3/c1-16(2,21-14-7-5-13(17)6-8-14)15(19)20-11-12-4-3-9-18-10-12/h3-10H,11H2,1-2H3
| Molecular Formula | C16H16ClNO3 |
| Molecular Weight | 305.756 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Nicofibrate is an antilipidemic drug. Treatment of diabetics led to a significant reduction in plasma cholesterol and triglycerides and brought the lipoprotein picture back within the norm. Nicofibrate did not lead to significant increases in uricaemia nor to any worsening in carbohydrate tolerance. Nicofibrate may also lead to a significant drop in plasma prothrombinic activity.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:12 GMT 2025
by
admin
on
Mon Mar 31 18:14:12 GMT 2025
|
| Record UNII |
4839MB71E7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98150
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90185815
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
1915
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
100000084171
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
C75259
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
4839MB71E7
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
31980-29-7
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106799
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
65778
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
3388
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
250-880-7
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
SUB09236MIG
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | |||
|
m364
Created by
admin on Mon Mar 31 18:14:12 GMT 2025 , Edited by admin on Mon Mar 31 18:14:12 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |